Literature DB >> 26741128

Testicular cancer: germ cell tumours.

Peter Chung1, Padraig Warde.   

Abstract

INTRODUCTION: More than half of painless solid swellings of the body of the testis are malignant, with a peak incidence in men aged 30 to 34 years. Most testicular cancers are germ cell tumours and half of these are seminomas, which tend to affect older men and have a good prognosis. METHODS AND OUTCOMES: We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of treatments following orchidectomy in men diagnosed with stage 1 germ cell tumours (confined to testis)? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview).
RESULTS: At this update, 76 records were screened for inclusion. Appraisal of titles and abstracts led to the exclusion of 47 studies and the further review of 29 full publications. Of the 29 full articles evaluated, two systematic reviews and one RCT, were added at this update. Data from long-term follow-up of an already reported study were also added. We performed a GRADE evaluation for seven PICO combinations.
CONCLUSIONS: In this systematic overview, we categorised the efficacy for seven interventions based on information about the effectiveness and safety of adjuvant chemotherapy (including different drugs and the number of cycles), adjuvant radiotherapy (including different regimens), adjuvant surgery, and surveillance/observation.

Entities:  

Mesh:

Year:  2016        PMID: 26741128      PMCID: PMC4704678     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  21 in total

Review 1.  Regular review: Managing testicular cancer.

Authors:  D Dearnaley; R Huddart; A Horwich
Journal:  BMJ       Date:  2001-06-30

2.  Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

Authors:  R Timothy D Oliver; Graham M Mead; Gordon J S Rustin; Johnathan K Joffe; Nina Aass; Robert Coleman; Rhian Gabe; Philip Pollock; Sally P Stenning
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.

Authors:  Klaus-Peter Dieckmann; Peter Albers; Johannes Classen; Maike De Wit; Uwe Pichlmeier; Oliver Rick; Ulrich Müllerleile; Markus Kuczyk
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

Review 4.  Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.

Authors:  M D Shelley; K Burgon; M D Mason
Journal:  Cancer Treat Rev       Date:  2002-10       Impact factor: 12.111

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 6.  Increasing incidence of testicular cancer worldwide: a review.

Authors:  Eric Huyghe; Tomohiro Matsuda; Patrick Thonneau
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

7.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

9.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Authors:  M H Cullen; S P Stenning; M C Parkinson; S D Fossa; S B Kaye; A H Horwich; S J Harland; M V Williams; R Jakes
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

Review 10.  Management of stage I non-seminomatous testicular cancer: a systematic review and meta-analysis.

Authors:  S J Hotte; L A Mayhew; M Jewett; J Chin; E Winquist
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-10-17       Impact factor: 4.126

View more
  3 in total

Review 1.  The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis.

Authors:  Qiangzhao Liu; Qiong Lian; Haidi Lv; Xiaofeng Zhang; Fenghai Zhou
Journal:  Mol Diagn Ther       Date:  2021-04-22       Impact factor: 4.074

2.  The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage.

Authors:  Y Xue; A Raharja; W Sim; E S M Wong; S A B Rahmat; D P Lane
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

3.  The relationship of neutrophil to lymphocyte ratio with testicular cancer.

Authors:  Abdullah Ilktac; Bayram Dogan; Cevper Ersoz; Muzaffer Akcay; Habib Akbulut
Journal:  Int Braz J Urol       Date:  2020 Jan-Feb       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.